JP2024504260A5 - - Google Patents

Info

Publication number
JP2024504260A5
JP2024504260A5 JP2023537587A JP2023537587A JP2024504260A5 JP 2024504260 A5 JP2024504260 A5 JP 2024504260A5 JP 2023537587 A JP2023537587 A JP 2023537587A JP 2023537587 A JP2023537587 A JP 2023537587A JP 2024504260 A5 JP2024504260 A5 JP 2024504260A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
approximately
subject
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504260A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/063639 external-priority patent/WO2022132981A1/en
Publication of JP2024504260A publication Critical patent/JP2024504260A/ja
Publication of JP2024504260A5 publication Critical patent/JP2024504260A5/ja
Pending legal-status Critical Current

Links

JP2023537587A 2020-12-16 2021-12-15 セリンおよびグリシンの制限の調節およびそれらの制限に対する感受性化のための方法 Pending JP2024504260A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063126294P 2020-12-16 2020-12-16
US63/126,294 2020-12-16
US202163168414P 2021-03-31 2021-03-31
US63/168,414 2021-03-31
US202163170805P 2021-04-05 2021-04-05
US63/170,805 2021-04-05
PCT/US2021/063639 WO2022132981A1 (en) 2020-12-16 2021-12-15 Methods for modulation of and sensitization to serine and glycine limitation

Publications (2)

Publication Number Publication Date
JP2024504260A JP2024504260A (ja) 2024-01-31
JP2024504260A5 true JP2024504260A5 (cg-RX-API-DMAC7.html) 2024-12-20

Family

ID=82023934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537587A Pending JP2024504260A (ja) 2020-12-16 2021-12-15 セリンおよびグリシンの制限の調節およびそれらの制限に対する感受性化のための方法

Country Status (6)

Country Link
US (1) US20220193447A1 (cg-RX-API-DMAC7.html)
EP (1) EP4262787A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024504260A (cg-RX-API-DMAC7.html)
AU (1) AU2021403024A1 (cg-RX-API-DMAC7.html)
CA (1) CA3205385A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022132981A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069462A (zh) 2016-02-23 2018-12-21 癌症研究科技有限公司 缺乏至少两种非必需氨基酸的膳食产品
JP2023530235A (ja) 2020-06-03 2023-07-14 フェス・セラピューティクス，インコーポレーテッド 個別化された処置方法のための製剤
WO2021247923A1 (en) 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer
WO2025029650A1 (en) 2023-07-28 2025-02-06 Li Xiyan Nutritionally modified diets comprising aminoacids for use in treating a disease
WO2025208086A1 (en) * 2024-03-29 2025-10-02 Faeth Therapeutics, Inc. Dietary regimens and methods for treatment of colorectal cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921133A (zh) * 2015-09-04 2018-04-17 国立大学法人大阪大学 癌症的饮食疗法开发
CN109069462A (zh) * 2016-02-23 2018-12-21 癌症研究科技有限公司 缺乏至少两种非必需氨基酸的膳食产品
JP7623784B2 (ja) * 2016-10-13 2025-01-29 ジュノー セラピューティクス インコーポレイテッド トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
CA3119300A1 (en) * 2017-11-13 2019-05-16 Cancer Research Technology Ltd. Dietary product
WO2021247923A1 (en) * 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer

Similar Documents

Publication Publication Date Title
JP2024504260A5 (cg-RX-API-DMAC7.html)
AU2011287292B2 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
JP2021523122A5 (cg-RX-API-DMAC7.html)
JP7491220B2 (ja) 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療
JP2021513540A5 (cg-RX-API-DMAC7.html)
JP2021513541A5 (cg-RX-API-DMAC7.html)
JP2021510697A5 (cg-RX-API-DMAC7.html)
JP2023507190A5 (cg-RX-API-DMAC7.html)
CN101547705A (zh) 用于治疗新生物的组合物和方法
RU2007135167A (ru) Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака
RU2018103064A (ru) Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли
JP2021523233A5 (cg-RX-API-DMAC7.html)
JP2022541591A5 (cg-RX-API-DMAC7.html)
US20200399377A1 (en) Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen
JP2019516767A (ja) 癌の治療のためのペンブロリズマブとアベマシクリブとの組合せ
JP2024534602A5 (cg-RX-API-DMAC7.html)
JP2021520368A5 (cg-RX-API-DMAC7.html)
JP2023519807A5 (cg-RX-API-DMAC7.html)
US20230398229A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
JP2023502876A5 (cg-RX-API-DMAC7.html)
JP2025515092A5 (cg-RX-API-DMAC7.html)
JP2023520771A5 (cg-RX-API-DMAC7.html)
JP2023505222A5 (cg-RX-API-DMAC7.html)
JP2022517415A5 (cg-RX-API-DMAC7.html)
JP2025509567A5 (cg-RX-API-DMAC7.html)